Last updated: May 29, 2026
ANORO ELLIPTA suppliers: who manufactures vilanterol and umeclidinium, inhaler devices, and outsourced packaging?
ANORO ELLIPTA is a GSK (GlaxoSmithKline) branded inhaled product in the US combining umeclidinium (UMEC) and vilanterol (VI). Supply chains for combination inhalers typically split across (1) drug substance manufacture for each active, (2) finished-dose manufacture of the inhaler blend, (3) device manufacturing (the ELLIPTA platform), and (4) packaging, labeling, and secondary packaging.
No complete, reliable supplier roster can be produced from the information provided. Without specific, citable source material (e.g., FDA Orange Book/Drug Master File references, EU manufacturing authorization statements, or GSK procurement disclosures), listing “suppliers” would risk inaccurate attribution of contract manufacturers and device makers.
What suppliers make ANORO ELLIPTA (umeclidinium and vilanterol), and who supplies the ELLIPTA device?
Direct answer: A complete, defensible supplier list requires source-backed attribution to specific manufacturing sites and third parties (contract manufacturing organizations, device supply partners, and packaging vendors).
Active pharmaceutical ingredients (API) supply for umeclidinium and vilanterol
ANORO ELLIPTA’s supply chain for UMEC and VI generally includes:
- API synthesis and isolation for umeclidinium and vilanterol
- API purification and QC release
- GMP drug product blending and filling into ELLIPTA inhaler dose units
Drug product manufacturing and ELLIPTA device platform
ELLIPTA device supply typically includes:
- Dose counter and internal mechanisms
- Dry powder reservoir and blistering/strip system
- Metering components and inhalation pathway parts
- Device component assembly and integration with drug dose units
Where supplier evidence must come from
A supplier roster for ANORO ELLIPTA is usually only defensible when anchored to at least one of:
- FDA listing of manufacturing sites for the approved NDA product
- DMF references tied to drug substance (for UMEC, VI)
- European Medicines Agency product information and manufacturing authorization holders
- Confirmed manufacturer-of-record and packaging site listings from product labels and submission documents
Which contract manufacturers supply the finished-dose ANORO ELLIPTA inhaler in the US?
Direct answer: A correct answer must enumerate the manufacturing site(s) and the marketing authorization holder’s listed manufacturers-of-record for drug product and packaging.
Manufacturing-of-record fields to capture
A supplier map should split:
- Drug product manufacturing site(s)
- Primary packaging site(s) (dose unit blistering/strip system)
- Secondary packaging and labeling site(s)
- Sterile vs non-sterile is not the deciding factor here (dry powder inhaler), but the manufacturing steps and QC release are.
Who packages ANORO ELLIPTA (secondary packaging, labeling, NDC-level supply)
Direct answer: Packaging suppliers must be sourced from NDC-level label manufacturing and packaging site listings. Without those, any supplier attribution would be speculative.
What matters for packaging vendors
- Carton and leaflet printing
- Tamper-evident and distribution packaging
- Batch-level labeling and imprint/lot correlation
- Serialization and traceability (where applicable)
How does the ANORO ELLIPTA supply chain compare with other GSK dry powder inhalers on ELLIPTA (e.g., Trelegy Ellipta components)?
Direct answer: ELLIPTA-family products share the device platform and often share device manufacturing ecosystems, but the drug product manufacturing sites and packaging vendors may differ by SKU, strength, and market.
Comparison dimensions
- Device supply continuity across brands
- Drug substance vendors and DMF sources
- Drug product fill-finish sites and technology transfers
- Packaging and labeling contracts by market region
What is the FDA and Orange Book status of ANORO ELLIPTA suppliers (manufacturing site listings)
Direct answer: Orange Book is not a supplier register. Supplier identification typically comes from FDA product labeling and manufacturing site disclosures rather than patent listings. A supplier answer must point to FDA-labeled manufacturers-of-record.
Orange Book vs manufacturing disclosure
- Orange Book: patents and exclusivity, not supplier-of-record
- FDA label: often includes manufacturer/distributor and site identifiers
- FDA application and DMF cross-references: can evidence drug substance sources
Which companies are challenging ANORO ELLIPTA supply (biosimilar-like threats, generics, device competition)
Direct answer: Supply-chain challengers are not a biosimilar issue because ANORO ELLIPTA is a small-molecule combination inhaler. Competition risks come from:
- Generic/ANDA entrants for umeclidinium/vilanterol products
- Device-compatibility or bridging requirements for ANDA product development
Supplier risk channels for the brand
- Contract shifts if manufacturers lose commercial volume
- Regulatory action against manufacturing sites
- Quality incidents that trigger lot-level or site-level recalls
What manufacturing/IP barriers affect alternative suppliers of ANORO ELLIPTA inhalers
Direct answer: Barriers are usually:
- Patented formulation, particle engineering, and device integration features for dry powder inhalers
- Manufacturing process patents tied to blend characteristics, particle size distribution, and metering behavior
- Trade dress and device-specific delivery performance data expectations for ANDAs
Why supplier mapping must be evidence-based
Supplier decisions depend on:
- Regulatory compliance record of specific sites
- Ability to replicate performance (emitted dose, fine particle fraction, aerodynamic properties)
- Inhaler device integration constraints with the dosage unit
Key takeaways
- A complete, accurate ANORO ELLIPTA supplier list requires citable evidence of manufacturing and packaging site attribution.
- Without source-backed manufacturing-of-record data for UMEC, VI, dose-unit drug product, and ELLIPTA device integration, any “supplier” roster would be unreliable.
- The correct supplier map should split by drug substance, drug product manufacturing, primary packaging, secondary packaging and labeling, and device component sourcing.
FAQs
- Which sites manufacture umeclidinium and vilanterol for ANORO ELLIPTA?
- Who manufactures the ELLIPTA device used in ANORO ELLIPTA?
- What packaging and labeling suppliers support ANORO ELLIPTA distribution in the US?
- Do ANORO ELLIPTA suppliers differ by NDC strength or pack size?
- How do generic ANDA entrants source inhaler devices and dry powder dose units versus the brand?
References
- (No citable sources were provided in the prompt.)
